Braindrp
The biotech licensing portal.
Scroll ↓Company purpose
Braindrop is the world's first end-to-end integrated IP infrastructure for biotech dealmaking.
Pharma's $350B problem
Biotech deals are complex…
Patent to shelf
Milestone payments for drug deals.
Negotiation
0 –12 months
After R&D and IP diligence, commercial negotiations still take 8 to 12 months to close.
Cost of delay
+$ 0 M per day
Each day a blockbuster patent deal sits in negotiation, pharma loses over $2.7M in revenue.
"… and yet, the IP industry still lacks a shared technology layer."
Biotech's patent liquidity problem
“Every time I email my attorneys it costs me… $1,000.”
New York biotech founder · June 2026
$500K–$1M+
Incumbent IP software, per year
And it still covers only 1–2 of the functions a deal needs.
Priced out
What a venture-backed biotech can spend
Instead, work runs on:
Excel the portfolio 
PowerPoint the pitch 
Email the deal 
Outside counsel $1,000+ / email The solution
Shared infrastructure = liquidity.
Excel portfolio
↓
Braindrop
Dashboard
View every patent, fee, and milestone with fintech-inspired UX pharma deserves.
PowerPoint pitch
↓
Braindrop
Data Room
Securely share assets and market intelligence with any counterparty.
Email deal
↓
Braindrop
Deal Room
Multi-party negotiations, embedded contracts, and auditable ledgers of milestones.
All for $30K/year per company.
The solution (02)
Braindrop cuts deal lead-times by over 50% — a win-win for both sides of the market.
→
Pharma BD lead
Waste less time on bad deals — get the good ones to market quicker.
←
Biotech founder
10× the liquidity opportunities, at a fraction of the existing cost (a lifeline)
Why now
Big pharma's international shopping addiction is about to get worse.
- China now sources ~30% of the global biotech pipeline.
- Internal R&D no longer fills the gap.
- Clinical trials accelerated by AI.
= more deals to get done
$350bn
Revenue off the patent cliff
2031
So we're building global shopping rails.
Market size
$0B
annual market, built on multi-year deal payouts and network effects.
Two engines: a platform subscription every company can afford, and a percentage of every deal that runs on the rails.
Business model
Subscription, percentages… and deal data.
Biotech
$30K / year / company
Pharma
$30K / year / seat
Product
The NASDAQ started with ledgers. So do we.
Dashboard
Onboard your whole portfolio in minutes.
Manage
Manage a global estate in classes, not emails and letters.
Data room
Share assets and run auditable due diligence in seconds.
Deal room
License IP, accept offers, and track every milestone.
Positioning
Incumbent IP suites
$M+ multi-year contracts · pharma only
Braindrop
Under $100K / asset · biotech-accessible
Market traction
Tight feedback loops.
Pilot user
New York
Biotech (peptides), led by a Forbes 30 Under 30 founder.
Pilot user
Tokyo
In-licensing firm moving US assets into Japan.
Ongoing advisory
San Francisco
Partner at a law firm specialising in biotech IP litigation.
Ongoing advisory
Sweden
BD Lead at a pharma with a $15.95B USD market cap.
Team
Key team members include founders and lead engineers of infrastructure that now facilitate regulated trading volume of hundreds of millions of dollars per day, globally.
Team backgrounds include
